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Bovine colostrum (BC) is used in humans as a nutritional supplement for immune support
and has been shown to reduce Respiratory disease (RD). Other nutritional supplements,
minerals and vitamins including mannan oligosaccharides (MOS), zinc and vitamins A, C
and E have also been used for immune support. The aim of this prospective blinded
randomized clinical trial was to evaluate the effects of a BC, MOS, zinc and vitamin based
enhanced bovine colostrum supplement (BCS) on incidence and duration of RD occurring
in yearling horses. 109 yearlings on two Thoroughbred farms in Central Kentucky were
randomly assigned to treatment or placebo groups. Yearlings were supplemented once
daily for 17 to 25 weeks with 100 g of a high quality commercial BCS (containing 50 g BC)
or a full fat soy ﬂour placebo, which were applied as a “top-dress” to feed. Yearlings were
observed daily and evaluated weekly for signs of RD. All yearlings completed the study. The
proportion of the study period during which each yearling exhibited illness was consid-
erably shorter for BCS yearlings (least squares mean ¼ 23% of the study period) than
placebo yearlings (least squares mean ¼ 34% of the study period, P ¼ .002). The average
duration of illness was shorter for BCS yearlings (1.96 weeks) than placebo yearlings (4.39
weeks, P < .0001). There was no statistical difference in the incidence of RD in these study
yearlings.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bovine colostrum (BC) is the ﬁrst milk produced by
cows after calving. Bovine colostrum contains immuno-
globulins, other immune factors, growth factors and otherIntegrated Medicine,
24.
ger).
nd Statistics, Califor-
rs. Published by Elsevier Innutrients necessary for optimal immunity, maturation, and
support of the neonatal calf. Recently, BC has become
increasingly popular as a nutritional supplement in
humans for immune support. In humans, BC has been
shown to be effective in prevention of inﬂuenza [1], upper
respiratory tract infections in children [2], upper respira-
tory tract infections in athletes [3], and to improve the
humoral immune response to vaccination [4]. This effect is
not limited to humans: Bovine colostrum supplementation
enhances the immune response in dogs to canine dis-
temper vaccine [5].c. This is an open access article under the CC BY-NC-ND license (http://
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response is not limited to BC. Mannan oligosaccharides
(MOSs) modify the cytokine response of pulmonary mac-
rophages in pigs [6]. Zinc has amyriad of direct and indirect
effects on the immune system, via both its role as a cofactor
in over 300 enzymes, its direct effects on leukocytes [7] and
on the humoral immune response [8]. Vitamins A [9], C
[10], and E [11] have well-described beneﬁts on immune
function in animals.
Equine respiratory disease (RD) is a signiﬁcant cause of
morbidity in horses, and young horses are signiﬁcantly
more susceptible to RD than older horses [12]. Respiratory
disease is the second leading cause of missed training days
in racehorses and is responsible for almost a quarter of lost
training days [13]. Inﬂuenza, herpesviruses, and rhinitis
viruses are among the most common causes of viral res-
piratory infection in horses, whereas Streptococcus zooepi-
demicus, Actinobacillus or Pasteurella spp, coagulase
negative Staphylococcus, or nonhemolytic Streptococcus are
the most common cause of bacterial respiratory infection,
with younger horses (2 years of age and less) highly sus-
ceptible to primary viral disease and secondary bacterial
superinfection [12]. Supplements that support immune
function and mitigate these infections would beneﬁt the
equine industry.
This study was undertaken to determine if a BC; MOS;
zinc; and vitamins A, C, and E containing supplement
(ImmHand EQ Animed, Winchester, KY) has a disease-
sparing effect for RD in Thoroughbred yearlings.
2. Materials and Methods
2.1. Study Facilities and Animals
Privately owned Thoroughbred yearlings residing on
two farms in Central Kentucky were used throughout.
These yearlings consisted of all farm yearlings, both resi-
dent foaled and purchased from sales before and during the
study period. There was no quarantine instituted for horses
added to the farm during the study period. Horses were
housed and fed according to farm management procedures
and identiﬁed by mare names on halter name tags, which
consisted of either a brass name plate or a cattle ear tag
afﬁxed to the halter with the name indicated on the tag. All
horses were vaccinated and dewormed according to farm
protocols, which included a primary series of vaccinations
for Eastern, Western, and West Nile Equine Encephalitis
viruses, tetanus, botulism, inﬂuenza, and rhinopneumoni-
tis with boosters in March. Deworming consisted of a
2-month rotational deworming program of pyrantel
pamoate, anthelcide, and ivermectin during the study
period. Horses were stabled in 120  120 stalls bedded in
straw, shavings, or bluegrass bedding. On farm A, yearlings
were brought into the barn and fed separately twice daily.
Fillies were housed in a communal paddock and colts in an
adjacent paddock, and treatment and placebo groups were
commingled. On farm B, yearlings were brought into the
barn and fed once daily 5 days per week and fed outside in
communal feeders once daily 5 days per week and twice
daily for the remaining 2 days. On farm B, colts and ﬁllies
were similarly separated, but the placebo and treatmentgroups were not commingled. Groups were housed
separately in adjacent paddocks. The distribution of the
yearlings among farms, treatment groups, and gender is
shown in the Table. The study protocol was approved by
the Institutional Animal Care and Use Committee of Equine
Integrated Medicine PLC, and the owner or his or her
designee (i.e., the farm manager) provided informed
consent for all horses participating in the study.
2.2. Bovine Colostrum
The colostrum used in this trial was produced under
USDA and CFIA (Canadian Food Inspection Agency) permits
for commercial use as a veterinary biologic. Excess colos-
trum was collected from dairies licensed to produce milk
for human consumption and stored frozen until processing.
The thawed colostrum was pasteurized using a
proprietary method (Saskatoon Colostrum Company, Ltd,
Sasketchewan, Canada) developed to eliminate pathogenic
contaminants while maintaining the integrity of the im-
mune factors and spray dried. The spray-dried colostrum
was tested for retention of potency using a radial immu-
nodiffusion method for IgG and for safety using standard
microbiological methods for total plate counts, coliforms,
and salmonella. The BC powder was then packaged into a
blended nutritional supplement with MOSs; vitamins A, C,
and E; zinc; and folic acid (ImmHand EQ) in a GMP facility
(Animal Healthcare Products and Packaging, Inc,
Winchester, KY) before being shipped to the study location.
Placebo was soy ﬂour, selected to match color, and con-
sistency of the test article. No attempt was made to match
the protein, fat, or other dietary ingredients because the
supplement comprised less than 3% of the total diet and
was not considered to have a substantial impact on the
balance of the macronutrients of the diet.
2.3. Experimental Design
All yearlings housed on the two farms were included in
this randomized blinded prospective placebo controlled
study. Horses were randomly assigned to the treatment or
placebo groups. Horses in the treatment group received
100 g ImmHand EQ (containing 50 g BC) (BCS group) as a
feed top dress once daily, and horses in the placebo group
received 100-g soy ﬂour (P group) as a feed top dress once
daily. On farm A, the supplement or placebo was fed once
daily in the morning feed. On farm B, The supplement or
placebo was fed once daily in the morning feed which was
offered when the horses were in the stalls 5 days per week
and in the communal feeders 2 days a week when they did
not come into the stalls. Supplementation was initiated in
the yearlings in mid-January, or when the horse was added
to the farm, and discontinued in June, unless the horse left
the farm before June. On farm A, the study period for the
yearlings averaged 22 weeks (range, 17–23), and on farm B,
the study period averaged 22.6 weeks (range, 6–26).
2.4. Variables Recorded
Yearlings were observed daily by farm personnel and
assessed once weekly for evidence of respiratory tract
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The farm manager and yearling managers were trained by
the study principle investigator (C.K.F.), and either manager
performed all observations. The incidence (number of
times yearlings were affected during the study) and dura-
tion of illness (number of sequential weeks during which
yearlings were observed to be affected) were recorded. Any
missed observations were omitted from the analysis.
Antibiotic or other treatment for RD was intended to be
instituted if yearlings became anorectic, which did not
occur in any yearlings during this study.Fig. 2. Average number of weeks duration of each incident of respiratory
disease in yearlings, which was the number of weeks with respiratory dis-
ease divided by the umber of incidents of respiratory disease: least squares
means 1.96 standard error (* indicates signiﬁcant difference from placebo).
RD, respiratory disease.2.5. Data Analysis
The analysis of variance, controlling for nonrandom in-
ﬂuences of farm and gender, was ﬁtted to the data.
Normality in each of the independent variables was deter-
mined by visual inspection of normality plots and Ander-
son–Darling test of normality and analyzed using a general
linear model (PROC GLM SAS Institute Inc, Cary, NC).
3. Results
A total of 109 yearlings were in the study. Three
response variables were measured: one/proportion of the
study period each yearling was sick (proportion), two/
mean number of weeks affected per incident per yearling
(weeks/incident), and three/incidence rate of sickness
during the study period (incidence). Using PROC GLM in
SAS (SAS Institute Inc, Cary, NC), the response variables
were estimated using a completely randomized block
design, with blocks consisting of both gender and farm.
Because the treatment groups were not balanced, Type 3
sums of squares were used throughout.
After controlling for both gender and farm, analysis of
variance F-tests indicated differences by treatment groups
of the response variables proportion (P value ¼ .002, Fig. 1)
and weeks/incident (P value < .0001, Fig. 2), but no sta-
tistical signiﬁcance for incidence (P value ¼ .41, Fig. 3). The
least squares means for proportion was 0.23 for BCS group
and 0.34 for P group. The yearlings in the BCS group
exhibited signs of respiratory illness for less than one-0
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Fig. 1. Proportion of the study period, which was the number of weeks
during which the yearlings exhibited respiratory disease divided by the total
number of study weeks for that individual for the placebo and BCS groups:
least squares means þ 1.96 standard error (* indicates signiﬁcant difference
from placebo). RD, respiratory disease; BCS, bovine colostrum supplement.quarter of the study period, whereas yearlings in the P
group had signs of respiratory illness for one-third of study
period. Thus, yearlings in the BCS group were affected with
RD for shorter durations (1.96 weeks) during the study
period despite experiencing the same incidence of RD
during this time as compared to yearlings in the P group
(4.39 weeks).
The residuals from the models, proportion, weeks/inci-
dent, and incidence are not normally distributed, as tested
by the Anderson–Darling test for normality. However,
analysis using the central limit theorem provides reassur-
ance about the estimated parameters because the sample
sizes for the overall models were large (n ¼ 109) with 56
yearlings in treatment group BCS and 53 in treatment group
P. Only in the model ﬁtted to the response variable weeks/
incident did any signs of heteroskedasticity (variance was
not equal between the two groups) exist and was predom-
inantly due to a few outliers, discussed further below.
The heteroskedasticity found in the model for the
response variable weeks/incident was largely due to three
horses, all in the placebo group, with studentized residuals
greater than 3. Furthermore, for both response variables
proportion and incidence, one colt in the BCS group had an
extraordinarily large studentized residual of 3.3 for pro-
portion and 4.5 for incidence. The models were reﬁtted for
all three response variables without their respective0
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Fig. 3. Incidence of respiratory disease among yearlings, which was the
number of times yearlings exhibited respiratory disease divided by the
number of animals in the study: least squares means 1.96 standard error.
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above were identiﬁed.
3.1. Discussion
This study demonstrated that daily use of a BCS (Imm-
Hand EQ), a feed supplement product containing BC; MOS;
zinc; and vitamins A, C, and E resulted in a lower propor-
tion of time affected with RD and shorter duration of illness
per event in Thoroughbred yearlings. This effect is consis-
tent with ﬁndings in humans receiving BC oral supple-
mentation. Several studies in people have documented the
effects of BC supplementation on the incidence and/or
severity of RD, including a lower incidence of inﬂuenza-like
symptoms [1,14], respiratory tract symptoms in children
[2], and in athletes [3]. These studies demonstrated a
decreased incidence of RD with BC supplementation,
whereas our study demonstrated a decreased number of
days affected, but no difference in incidence of RD between
supplemented and placebo yearlings. One possible expla-
nation for this disparate ﬁnding in RD incidence between
the species is the management differences between horses
and humans. Humans can avoid contact with their peers
when there is contagious RD in a group, whereas horses are
maintained in comingled herds, and there were no isola-
tion procedures in place when horses became affected on
either of the two farms. However, a clear disease sparing of
the BC effect was evident by the shortened duration of RD
per incident in the yearlings being fed the immune
enhanced formulation in this study.
Additional ingredients in ImmHand EQ may have been
responsible for the observed RD sparing effect. Mannan
oligosaccharides are functional carbohydrates which are
not digested, but exert their action principally within the
intestinal tract. Mannan oligosaccharide effects include
local binding of type-1 ﬁmbria of pathogenic bacteria, such
as salmonella and Escherichia coli [15], and local effects in
the intestines of increasing protective mucus production in
sea bass [16], and altering cytokine proﬁles in pigs [6].
Despite the localization of the MOS within the intestinal
tract, there is evidence that MOS directly stimulates alve-
olar macrophages, indicating that it exerts some effect on
pulmonary immunity [6].
Zinc effects on the immune system include its role as
cofactor in over 300 enzymes, direct and indirect effects on
leukocytes [7]. Zinchas longbeen identiﬁed tohaveantiviral
properties against herpes viruses [17] and rhinoviruses [18]
in humans. Similar to the RD among yearlings in this study,
zinc administration in rhinovirus infected humans resulted
in a decreased duration of RD [18], suggesting that zinc may
have played an important role in mitigating disease in our
study. A relationship has been identiﬁed between zinc
supplementation and decreased risk of equine herpes
myelitis [19], further suggesting that zincmay play a similar
role in horses as in humans against respiratory viruses.
No attempts to identify the etiologic agent(s) of the RD
were made in our group, which is a drawback to our study.
The identiﬁcation of RD was by visual inspection, which
makes the identiﬁcation of the initial serous nasal discharge
associated with viral infection difﬁcult. Typically, by the
time a mucopurulent nasal discharge is identiﬁed, theprimary viral insult cannot be identiﬁed. However, themost
likely viral agents are inﬂuenza, equine rhinitis virus, Equine
Herpes Viruses (EHV-1, EHV-2, and EHV-4) [20], whereas
bacterial pathogens would most likely be S. zooepidemicus,
Actinobacillus or Pasteurella spp, coagulase negative Staph-
ylococcus, or nonhemolytic Streptococcus [12]. Transmission
of these pathogenic agents is by droplet inhalation, and BC
has been shown to increase salivary IgA in athletes [21],
whichmayhave contributed to themechanismbywhich the
BCS mitigated disease in Thoroughbred yearlings. All year-
lings had been vaccinated with a primary series of vacci-
nations in thepreceding year andwereboosteredduring the
study, which would have confounded any analysis of viral
titers, so such analysis was not performed.
Any contribution of the BC to the RD disease-sparing
effects could be due to the direct action of colostral anti-
microbial factors or to indirect effects of cytokines and
growth factors potentially enhancing the innate or acquired
immune response [22]. Direct effects could be due to
antibacterial and antiviral activities of molecules such as
lactoferrin and lactoperoxidase that could directly interfere
with transmission of infectious agents in the respiratory
tract following oral or nasal exposure. Indirect effects on
the immune response could be due to impacts of high
levels of growth factors such as insulin-like growth factor 1
(IGF1) and epidermal growth factor (EGF) or to regulatory
events from impacts of colostral cytokines (interleukin [IL]-
1beta, IL-2, IL-6, IL-17, tumor necrosis factor-alpha, inter-
feron-gamma, IL-10) on the cytokine network that
regulates immune responses.
In human studies, BC has multiple immune system ef-
fects in athletes, including increased salivary IgA in runners
[23], improvement in the recovery of neutrophil function
and maintenance of salivary lysozyme concentrations in
cyclists [24], and prevention of the TH-2 immune sup-
pression associated with exercise in cyclists [25]. When
used in combinationwith vaccination, BC has enhanced the
humoral response to vaccine in both humans [4] and dogs
[5]. The mechanisms of the effects of this BC containing
supplement on the horses in this study were not investi-
gated; however, they are presumably similarly associated
with an immune modifying effect of the BC or direct anti-
microbial effects in the upper respiratory tract.
Asmany as 16% of young Thoroughbreds are sidelined as
a result of RD, and it is the second leading cause of missed
training days [13]. A previous study [26] showed no effect
of BC on RD in horses in race training, but the authors felt
that this was likely a result of the low incidence of RD in
this cohort of horses. The authors hypothesized that
investigating an age group that experienced a higher rate of
RD would produce more meaningful results, which led to
the present study in younger individuals more susceptible
to RD. In addition, the previous study included only BC and
not the other ingredients in the BCS used here (MOSs; vi-
tamins A, C, and E; zinc; and folic acid), which likely
contributed to the immune effect.
4. Conclusion
A BC-based supplement was highly beneﬁcial for
reducing the duration of RD in Thoroughbred yearlings and
C.K. Fenger et al. / Journal of Equine Veterinary Science 42 (2016) 77–81 81provides a useful nonpharmacologic alternative for
reducing the adverse impact of RD in Thoroughbred
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